HK1214863A1 - 蛋白酶在中性粒細胞胞外誘捕網中的底物性質 - Google Patents

蛋白酶在中性粒細胞胞外誘捕網中的底物性質 Download PDF

Info

Publication number
HK1214863A1
HK1214863A1 HK16102826.8A HK16102826A HK1214863A1 HK 1214863 A1 HK1214863 A1 HK 1214863A1 HK 16102826 A HK16102826 A HK 16102826A HK 1214863 A1 HK1214863 A1 HK 1214863A1
Authority
HK
Hong Kong
Prior art keywords
protease
sample
subject
net
netosis
Prior art date
Application number
HK16102826.8A
Other languages
English (en)
Chinese (zh)
Inventor
Ye Jin
John Murphy
Terry Hermiston
Original Assignee
拜耳医药保健有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拜耳医药保健有限公司 filed Critical 拜耳医药保健有限公司
Publication of HK1214863A1 publication Critical patent/HK1214863A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK16102826.8A 2013-03-15 2014-03-14 蛋白酶在中性粒細胞胞外誘捕網中的底物性質 HK1214863A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799658P 2013-03-15 2013-03-15
US61/799,658 2013-03-15
PCT/US2014/029040 WO2014144572A2 (en) 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps

Publications (1)

Publication Number Publication Date
HK1214863A1 true HK1214863A1 (zh) 2016-08-05

Family

ID=51538342

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102826.8A HK1214863A1 (zh) 2013-03-15 2014-03-14 蛋白酶在中性粒細胞胞外誘捕網中的底物性質

Country Status (7)

Country Link
US (1) US9958459B2 (https=)
EP (1) EP2997352A4 (https=)
JP (1) JP2016519761A (https=)
CN (1) CN105339780A (https=)
CA (1) CA2906124A1 (https=)
HK (1) HK1214863A1 (https=)
WO (1) WO2014144572A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3607320A4 (en) 2017-04-03 2021-04-21 The Regents of the University of California COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer
CN116157687A (zh) * 2020-07-20 2023-05-23 英斯梅德股份有限公司 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
CN113238050A (zh) * 2021-02-20 2021-08-10 吴炜 一种中性粒细胞胞外诱捕网的快速检测方法
CN113310963B (zh) * 2021-05-31 2023-12-01 四川大学华西医院 一种改进的中性粒细胞NETs免疫荧光检测方法
CN115267172A (zh) * 2022-07-29 2022-11-01 首都医科大学宣武医院 检测NSPs水平的物质在制备预测急性缺血性卒中患者预后产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453528C (en) * 2001-08-01 2011-07-26 Cellomics, Inc. Novel fusion proteins and assays for molecular binding
US8569275B2 (en) * 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
CA2567300A1 (en) 2004-05-20 2005-12-01 Astellas Pharma Inc. Method for examining interstitial cystitis
WO2006084210A2 (en) * 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
US20090298078A1 (en) 2006-09-29 2009-12-03 Leukocare Ag Method for the detection of an activation of the immune system or the extent of cell death
WO2010022281A1 (en) 2008-08-20 2010-02-25 Greystone Pharmaceuticals, Inc. Methods for using human neutrophil elastase as an indicator of active wound infection
AU2010265848B2 (en) 2009-06-26 2016-05-12 University Of Florida Research Foundation, Inc. Rapid bed-side measurement of neutrophil elastase activity in biological fluids
CA2773618A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase

Also Published As

Publication number Publication date
EP2997352A4 (en) 2017-03-01
WO2014144572A3 (en) 2014-11-06
WO2014144572A2 (en) 2014-09-18
CA2906124A1 (en) 2014-09-18
JP2016519761A (ja) 2016-07-07
CN105339780A (zh) 2016-02-17
US9958459B2 (en) 2018-05-01
US20160011209A1 (en) 2016-01-14
EP2997352A2 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
Nouailles et al. Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19
Wang et al. Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps
HK1214863A1 (zh) 蛋白酶在中性粒細胞胞外誘捕網中的底物性質
Nakorchevsky et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies
De Marco Verissimo et al. Qualitative and quantitative proteomic analyses of Schistosoma japonicum eggs and egg-derived secretory-excretory proteins
Bislev et al. Quantotypic properties of QconCAT peptides targeting bovine host response to Streptococcus uberis
US20070134261A1 (en) Effectors of innate immunity
Akuma et al. Catalytic activity and autoprocessing of murine caspase-11 mediate noncanonical inflammasome assembly in response to cytosolic LPS
Fogarty et al. Comparative study of excretory–secretory proteins released by Schistosoma mansoni-resistant, susceptible and naïve Biomphalaria glabrata
Plasman et al. Probing the efficiency of proteolytic events by positional proteomics
Zhang et al. Optimization of human dendritic cell sample preparation for mass spectrometry-based proteomic studies
IL312919B1 (en) Peptide assay to distinguish between full-length high molecular weight kinogen (HMWK) and cleaved HMWK
Horbach et al. Visualization of calpain-1 activation during cell death and its role in GSDMD cleavage using chemical probes
Reed et al. Extracellular Biotransformation of β‐Endorphin in Rat Striatum and Cerebrospinal Fluid
AU2014331938A1 (en) Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation
ES2703150T3 (es) Procedimiento de detección de por lo menos un mecanismo de resistencia a los glicopéptidos por espectrometría de masas
Duzzi et al. [des-Arg1]-Proctolin: A novel NEP-like enzyme inhibitor identified in Tityus serrulatus venom
US20240345084A1 (en) A method of detecting a population of macrophages
JP6502854B2 (ja) ポリユビキチン化基質の同定方法
Gibson et al. Unbiased proteomics following inflammasome activation identifies caspase targets in primary intestinal epithelial cells
Nakayasu et al. Multi-omic data integration links deleted in breast cancer 1 (DBC1) degradation to chromatin remodeling in inflammatory response
van der Wal et al. Exploring the ubiquitinome of proteasome inhibitor-resistant multiple myeloma cell lines treated with proteasomal deubiquitylase-inhibiting compounds
Yin Cooperation of A20 and ABIN-1 in counteracting CBM complex signaling in activated T cells
Sap et al. Depletion of the proteasome-associated deubiquitinase RPN11, but not UCHL5 and USP14, results in an extensive remodeling of the ubiquitinome.
Bagchi et al. Screening and Evaluation of Protease Inhibitory Peptides in Microcystis spp.–Dominant Water Blooms